BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251113T190000
DTEND;TZID=Africa/Nairobi:20251113T203000
DTSTAMP:20260526T003228
CREATED:20251110T143627Z
LAST-MODIFIED:20251223T151933Z
UID:40551-1763060400-1763065800@kesho-kenya.org
SUMMARY:Advances in Small-Cell Lung Cancer Treatment
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nDate: 13th November 2025Time: 7 PM – 8:30 PM EAT \n\nSpeakerDr. Riaz KasmaniMedical Oncologist\, Mombasa Cancer CentreSmall-Cell Lung Cancer: Advances\, Evidence and Clinical Challenges \n\nModeratorDr. Jumaa BwikaClinical Assistant Professor & Section Head\, Pulmonology\, Aga Khan Hospital \n\nOrganized by:KESHOKenya Society of Haematology & Oncology \nSupported by:BEACON Medicare Limited(Global Marketing Partner of BEACON Pharmaceuticals Limited) \nSummary: \nDr Kasmani presented an overview of Small Cell Lung Cancer (SCLC)\, focusing on disease biology\, treatment response\, relapse patterns and emerging research directions. \nSCLC accounts for a minority of lung cancer diagnoses yet contributes disproportionately to cancer-related mortality due to its aggressive behavior\, early dissemination and rapid development of treatment resistance. While the disease is initially highly chemo sensitive\, with high response rates to first-line therapy\, relapse is common and subsequent responses are often short-lived. \nThe presentation highlighted current staging approaches\, standard first-line treatment strategies for limited and extensive-stage disease and the evolving role of chemo-immunotherapy. Emphasis was placed on response assessment\, patterns of relapse and the clinical distinction between sensitive and refractory disease\, which continues to guide second-line treatment decisions. \nKey takeaway: Despite high initial response rates\, SCLC remains a challenging disease with frequent relapses\, underscoring the need for timely diagnosis\, evidence-based treatment and continued investment in research and clinical trials to improve patient outcomes.
URL:https://kesho-kenya.org/event/lung-cancer-treatment/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/11/WhatsApp-Image-2025-11-10-at-1.44.04-PM-e1762785377526.jpeg
END:VEVENT
END:VCALENDAR